Article info
PDFExtended reports
First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104
- Correspondence to:
Dr C Iking-Konert
Rheumazentrum Duesseldorf, Heinrich-Heine-University Duesseldorf; Iking-Konertmed.uni-duesseldorf.de
Citation
First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104
Publication history
- Accepted December 21, 2003
- First published August 12, 2004.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2004 by Annals of the Rheumatic Diseases